BridgeBio Pharma宣布，其Ascend-Attr研究项目已完成首位参与者的药物给药。这项3B/4期临床试验旨在深入评估Acoramidis在转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）治疗中对疾病逆转进程的长期影响。
此次里程碑式的进展标志着该研究正式进入患者入组阶段。Acoramidis作为一种在研药物，其潜在的疾病修饰能力备受关注——它能否真正推动ATTR-CM的病情逆转，正是这项研究希望解答的核心问题。
研究设计着眼于长期观察，力求全面刻画药物在真实临床场景下的疗效持久性与安全性轮廓。BridgeBio方面表示，Ascend-Attr研究将系统追踪患者在接受治疗后的多项临床指标变化，以判断疾病是否出现实质性逆转。
ATTR-CM是一种进行性、致命性的心肌疾病，长期以来缺乏能够直接逆转病程的治疗方案。业界对这一研究结果抱有期待——若数据积极，Acoramidis或将为这类患者群体带来全新的治疗选择，重塑现有的临床管理格局。
随着首位患者完成给药，研究的后续进展值得密切关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.